Virtual Library
Start Your Search
L. Zhu
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-019 - Sophoridine Inhibits Lung Cancer Cell Proliferation through Activating Hippo Signaling and P53 Pathway (ID 8046)
09:30 - 09:30 | Author(s): L. Zhu
- Abstract
Background:
Lung cancer is regarded as the most commonly diagnosed malignant disease with the leading cause of cancer-associated death. Sophoridine is a quinolizidine alkaloid extracted from Sophora alopecuroides L, a traditional Chinese medicine, which was found to have diverse pharmacological properties such as anti-inflammatory and anti-cancer. In our current research, we evaluated the effect of sophoridine alone and in combination with cisplatin on various human lung cancer cell lines and also explored the possible anti-cancer mechanisms underlie.
Method:
Colony formation assay, CCK-8 assay as well as transwell invasion and migration assay were adopted to investigate the anti-cancer effects of Sophoridine through a series of human lung cancer cell lines. Western-blot and Quantitative Real-time PCR were used to explore the possible underlying mechanisms of the inhibitory effect of Sophoridine on lung cancer progress.
Result:
We confirmed that Sophoridine can inhibit lung cancer cell proliferation, invasion and migration significantly. In addition, the Hippo-YAP pathway and p53 signaling might be involved in the inhibitory effect of Sophoridine in NCI-H446, NCI-H460 and A549 cell lines but not in the p53-deficient NCI-H1299 cells. Quantitative Real-time PCR showed that Sophoridine can dramatically suppress the downstream targets of Hippo-YAP1 pathway such as CYR61, CDX2, FOXM1, c-Myc and VEGF.
Conclusion:
In conclusion, our study first suggested that sophoridine might be used as a novel agent for lung cancer.
